RGL-270 vaccine plus immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new cancer vaccine (RGL-270) combined with immunotherapy drugs for advanced non-small cell lung cancer. The vaccine is designed to train your immune system to recognize and fight your specific cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (NSCLC) confirmed by biopsy or tissue sample
- You have at least one measurable tumor on imaging scans that hasn't been treated with radiation recently
- Your overall health and energy level allow you to manage daily activities with minimal help (ECOG 0–1)
- Your blood counts, liver, kidney, and heart function are within acceptable ranges
- You are willing to provide fresh or archived tumor tissue and blood samples for genetic testing
- You have not received prior immunotherapy, cancer vaccines, or radiation in the past 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (made from your own tumor's genetic fingerprint) combined with an immunotherapy drug called adebrelimab. The goal is to see if this combination can help prevent lung cancer from coming back or slow its growth.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests a new drug (QL1706) combined with bevacizumab, with or without chemotherapy, for people with advanced non-squamous non-small cell lung cancer that has grown after prior immunotherapy. It aims to see if this combination can help control the cancer.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This study tests a combination of a personalized vaccine made from your tumor's unique markers, a type of immunotherapy (PD-1 inhibitor), and radiation. The goal is to see if this mix can work better for advanced lung cancer that has progressed after initial treatment.
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.